GUMDROP : A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

Created by Nancy Dawson, last modified on May 19, 2013
Description:The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
Link:http://clinicaltrials.gov/ct2/show/NCT00859781
Site:Georgetown University Hospital
Principal Investigator:Dr. George Philips